Clinical Trials on Metastatic Triple-Negative Breast Carcinoma in Korea, Democratic People's Republic of
Total 322 results
-
Seoul National University HospitalTerminatedMetaplastic Breast CarcinomaKorea, Republic of
-
Yonsei UniversityNot yet recruitingTNBC - Triple-Negative Breast CancerKorea, Republic of
-
National Cancer Center, KoreaActive, not recruitingTriple Negative Breast CancerKorea, Republic of
-
Jeong Eon LeeAsan Medical Center; Seoul National University Hospital; Gangnam Severance Hospital and other collaboratorsActive, not recruiting
-
Asan Medical CenterCompletedBreast CancerKorea, Republic of
-
Yonsei UniversityRecruitingTriple Negative Breast Cancer | Metastatic Breast Cancer With HER2 PositiveKorea, Republic of
-
Samsung Medical CenterActive, not recruitingTriple Negative Breast Cancer | HER2-positive Breast CancerKorea, Republic of
-
Samsung Medical CenterRecruitingTriple Negative Breast Cancer | Immune Checkpoint InhibitorKorea, Republic of
-
Samsung Medical CenterRecruitingTriple Negative Breast Cancer | Pembrolizumab | Neoadjuvant Chemotherapy | Tumor MicroenvironmentKorea, Republic of
-
Genexine, Inc.Merck Sharp & Dohme LLCCompletedTriple Negative Breast CancerKorea, Republic of
-
Yonsei UniversityRecruitingBreast CancerKorea, Republic of
-
AstraZenecaActive, not recruitingMetastatic Triple Negative Breast CancerUnited States, Belgium, Italy, Spain, United Kingdom, Canada, Czechia, Poland, France, Korea, Republic of, Germany, Taiwan, Portugal, Netherlands, Ireland
-
Novartis PharmaceuticalsCompletedAdvanced Triple Negative Breast Cancer (TNBC) With High TAMsFrance, Italy, Austria, Taiwan, United States, Spain, Australia, Korea, Republic of, Belgium, Germany, Hong Kong, Turkey
-
Novartis PharmaceuticalsCompletedTriple-negative Breast CancerBelgium, Italy, Japan, Taiwan, United States, Australia, Singapore, Spain, Germany, Korea, Republic of, Argentina, Canada, France, Hungary, Israel, Lebanon, Thailand
-
Hoffmann-La RocheCompletedTriple-Negative Breast CancerUnited States, Korea, Republic of, Spain, Brazil, Taiwan, Germany, Russian Federation, Australia
-
Gilead SciencesActive, not recruitingTriple-Negative Breast CancerUnited States, United Kingdom, Australia, Hong Kong, Korea, Republic of, Taiwan
-
AstraZenecaCompletedPancreatic Ductal Adenocarcinoma | Triple-negative Breast Cancer | Urothelial Bladder CancerUnited States, Belgium, Korea, Republic of, Poland, Netherlands
-
Hoffmann-La RocheCompletedTriple-negative Breast CancerUnited States, Korea, Republic of, Canada, United Kingdom, Belgium, Brazil, Germany, Taiwan, Australia, Japan, Spain, Poland, Italy
-
Novartis PharmaceuticalsCompletedBreast CancerSpain, United Kingdom, Taiwan, Australia, Russian Federation, Germany, Korea, Republic of, Ireland, United States, Italy, Brazil, Czech Republic
-
CytomX TherapeuticsCompletedNeoplasms | Breast Cancer | Breast Neoplasms | Breast Neoplasms, Triple-Negative | Breast Neoplasms, Hormone Receptor Positive/HER2 NegativeUnited States, Spain, Korea, Republic of
-
Novartis PharmaceuticalsCompletedColorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell CarcinomaUnited States, Spain, Taiwan, Germany, Netherlands, United Kingdom, Korea, Republic of
-
G1 Therapeutics, Inc.Active, not recruitingBreast Cancer | TNBC - Triple-Negative Breast CancerUnited States, Spain, China, France, Australia, Georgia, Poland, Bulgaria, Moldova, Republic of, Russian Federation, Ukraine
-
Gangnam Severance HospitalSeoul National UniversityRecruitingBreast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive Tumor | Premenopausal Breast Cancer | Node-positive Breast CancerKorea, Republic of
-
Hoffmann-La RocheCompletedTriple-Negative Breast CancerIsrael, United States, Australia, Korea, Republic of, Belgium, Argentina, Denmark, Finland, Italy, Portugal, Spain, Taiwan, Thailand, Japan, United Kingdom, Brazil, Canada, Colombia, Mexico, France, Costa Rica, Switzerland, Czechia, P... and more
-
Hoffmann-La RocheTerminatedBreast CancerIsrael, Italy, Spain, United States, Belgium, Czechia, Australia, United Kingdom, Korea, Republic of, Romania, France, Taiwan, Latvia
-
Synta Pharmaceuticals Corp.CompletedBreast Cancer | Triple Negative Breast Cancer | HER-2 Positive Breast Cancer | ER/Progressive Response (PR) + Refractory to Prior Hormonal TreatmentSpain, United States, Argentina, Belgium, Brazil, Korea, Republic of, Peru, United Kingdom
-
EnhancedBio USA Inc.ZenopharmRecruitingMetastatic Breast Cancer | Locally Advanced Breast Cancer | HER2-Negative | Estrogen Receptor-PositiveUnited States, Korea, Republic of
-
Samsung Medical CenterRecruitingMetastatic Breast CancerKorea, Republic of
-
Seoul National University HospitalSeoul National University Bundang Hospital; Korean Cancer Study Group (KCSG); Eisai Korea Inc... and other collaboratorsActive, not recruitingMetastatic Breast CancerKorea, Republic of
-
Samsung Medical CenterUnknownBreast Cancer MetastaticKorea, Republic of
-
Samsung Medical CenterUnknownMetastatic Breast CancerKorea, Republic of
-
National Cancer Center, KoreaCompletedGoserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBCMetastatic Breast CancerKorea, Republic of
-
Korean Breast Cancer Study GroupUnknownMetastatic Breast CancerKorea, Republic of
-
OBI Pharma, IncRecruitingTriple Negative Breast CancerChina, Taiwan, United States, Korea, Republic of, Australia, Brazil, Hong Kong, Mexico, Russian Federation, South Africa, Ukraine, Peru, Poland
-
Korea University Guro HospitalRecruitingMetastatic Breast CancerKorea, Republic of
-
Yonsei UniversityNot yet recruiting
-
Asan Medical CenterEisai Inc.; Dong-A ST Co., Ltd.; Samyang Biopharmaceuticals CorporationCompletedMetastatic Breast CancerKorea, Republic of
-
Samsung Medical CenterCompletedMetastatic Breast CancerKorea, Republic of
-
CelltrionUnknownMetastatic Breast CancerKorea, Republic of
-
Gachon University Gil Medical CenterUnknownMetastatic Breast CancerKorea, Republic of
-
PfizerActive, not recruiting
-
Yonsei UniversityCompletedMetastatic Breast CancerKorea, Republic of
-
Korean Cancer Study GroupUnknownPhase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast CancerMetastatic Breast Cancer | HER2-positive Breast CancerKorea, Republic of
-
National Cancer Center, KoreaActive, not recruitingMetastatic Breast Cancer | HER2-positive Breast CancerKorea, Republic of
-
AVEO Pharmaceuticals, Inc.Astellas Pharma IncTerminatedTriple Negative Breast CancerGermany, Taiwan, Spain, Ukraine, Australia, Korea, Republic of, Canada, United States, Italy, Bahamas
-
Hoffmann-La RocheRecruitingBreast CancerKorea, Republic of, United States, Israel, Denmark, Argentina, Mexico, Brazil, Germany, Peru, Poland, Spain, Taiwan, South Africa, Czechia, Italy, Australia, Hungary
-
Samsung Medical CenterRecruitingBreast Cancer | Metastatic Breast Cancer | Radiation Therapy ComplicationKorea, Republic of
-
Asan Medical CenterCompletedMetastatic Breast CancerKorea, Republic of
-
Yonsei UniversityRecruitingMetastatic Breast Cancer | HER2-positive Breast Cancer | PostmenopausalKorea, Republic of
-
Hoffmann-La RocheCompletedSmall Cell Lung Carcinoma | Hepatocellular Carcinoma | Carcinoma, Non-Small Cell Lung | Urothelial Carcinoma | Triple Negative Breast CarcinomaKorea, Republic of